Literature DB >> 28130004

The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study.

Alex S Cohen1, Kyle R Mitchell2, Gregory P Strauss3, Jack J Blanchard4, Robert W Buchanan5, Deanna L Kelly5, James Gold5, Robert P McMahon5, Heather A Adams5, William T Carpenter5.   

Abstract

Entities:  

Keywords:  Acoustic; Computer; Galantamine; Negative; Oxytocin; Prosody; Schizophrenia

Mesh：

Substances：

Year:  2017        PMID： 28130004      PMCID： PMC5524598          DOI： 10.1016/j.schres.2017.01.028

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  8 in total

Review 1.  Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.

Authors:  Kazuto Oya; Yuki Matsuda; Shinji Matsunaga; Taro Kishi; Nakao Iwata
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-25       Impact factor: 5.270

Review 2.  Automated computerized analysis of speech in psychiatric disorders.

Authors:  Alex S Cohen; Brita Elvevåg
Journal:  Curr Opin Psychiatry       Date:  2014-05       Impact factor: 4.741

3.  Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.

Authors:  Mary R Lee; Heidi J Wehring; Robert P McMahon; Jared Linthicum; Nicola Cascella; Fang Liu; Alan Bellack; Robert W Buchanan; Gregory P Strauss; Carlo Contoreggi; Deanna L Kelly
Journal:  Schizophr Res       Date:  2013-02-13       Impact factor: 4.939

4.  Vocal expression in schizophrenia: Less than meets the ear.

Authors:  Alex S Cohen; Kyle R Mitchell; Nancy M Docherty; William P Horan
Journal:  J Abnorm Psychol       Date:  2016-02

5.  The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

Authors:  Robert W Buchanan; Daniel C Javitt; Stephen R Marder; Nina R Schooler; James M Gold; Robert P McMahon; Uriel Heresco-Levy; William T Carpenter
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

6.  Computerized facial analysis for understanding constricted/blunted affect: initial feasibility, reliability, and validity data.

Authors:  Alex S Cohen; Sean C Morrison; Dallas A Callaway
Journal:  Schizophr Res       Date:  2013-05-29       Impact factor: 4.939

7.  A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.

Authors:  Robert W Buchanan; Deanna L Kelly; Elaine Weiner; James M Gold; Gregory P Strauss; Maju M Koola; Robert P McMahon; William T Carpenter
Journal:  J Clin Psychopharmacol       Date:  2017-08       Impact factor: 3.153

Review 8.  Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Richard A Hansen; Gerald Gartlehner; Aaron P Webb; Laura C Morgan; Charity G Moore; Daniel E Jonas
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458
  8 in total
  3 in total

1.  Computerized analysis of facial expressions in serious mental illness.

Authors:  Tovah Cowan; Michael D Masucci; Tina Gupta; Claudia M Haase; Gregory P Strauss; Alex S Cohen
Journal:  Schizophr Res       Date:  2022-01-22       Impact factor: 4.939

2.  Ambulatory audio and video recording for digital phenotyping in schizophrenia: Adherence & data usability.

Authors:  Tovah Cowan; Alex S Cohen; Ian M Raugh; Gregory P Strauss
Journal:  Psychiatry Res       Date:  2022-02-25       Impact factor: 11.225

Review 3.  Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment.

Authors:  Kah Kheng Goh; Chun-Hsin Chen; Hsien-Yuan Lane
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.